ARTICLE | Clinical News
Optune survival readout boosts Novocure
September 12, 2016 7:00 AM UTC
Novocure Ltd. (NASDAQ:NVCR) gained $0.53 to $8.62 on Monday after it said a long-term analysis of a Phase III study showed Optune ( NovoTTF-100A) significantly improved survival after four years in patients with newly diagnosed glioblastoma multiforme.
The 695-patient EF-14 study evaluated Optune alone or in combination with temozolomide. The company said it will present the analysis at next month's Society for Neuro-Oncology meeting in Scottsdale, Arizona. ...